Edwards Lifesciences Corporation (EW) Given Average Rating of “Buy” by Analysts
Edwards Lifesciences Corporation (NYSE:EW) has earned an average rating of “Buy” from the twenty-two brokerages that are currently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation, fifteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $126.22.
A number of equities research analysts have recently issued reports on the stock. Cowen set a $135.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Sunday. BMO Capital Markets reissued a “buy” rating and set a $137.00 price target on shares of Edwards Lifesciences in a research report on Friday. Canaccord Genuity reissued a “buy” rating and set a $137.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, November 29th. Deutsche Bank dropped their price target on shares of Edwards Lifesciences from $122.00 to $115.00 and set a “hold” rating for the company in a research report on Thursday, October 26th. Finally, Morgan Stanley dropped their price target on shares of Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating for the company in a research report on Thursday, October 26th.
In related news, VP Donald E. Bobo, Jr. sold 5,300 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $108.86, for a total value of $576,958.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Schack Wesley W. Von sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $104.15, for a total transaction of $104,150.00. Following the completion of the transaction, the director now directly owns 2,622 shares in the company, valued at approximately $273,081.30. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 139,580 shares of company stock worth $14,849,205. Insiders own 2.13% of the company’s stock.
Edwards Lifesciences (NYSE EW) traded up $0.15 during mid-day trading on Monday, reaching $118.18. 1,313,423 shares of the company’s stock were exchanged, compared to its average volume of 1,641,483. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33. Edwards Lifesciences has a fifty-two week low of $86.55 and a fifty-two week high of $121.45. The stock has a market cap of $24,977.50, a PE ratio of 32.69, a PEG ratio of 2.11 and a beta of 0.51.
Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The business had revenue of $821.50 million during the quarter, compared to analysts’ expectations of $833.85 million. During the same period last year, the company posted $0.68 EPS. Edwards Lifesciences’s revenue for the quarter was up 11.1% on a year-over-year basis. sell-side analysts forecast that Edwards Lifesciences will post 3.76 earnings per share for the current fiscal year.
Edwards Lifesciences announced that its Board of Directors has approved a stock buyback plan on Thursday, December 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company’s board believes its stock is undervalued.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.